Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
Michael H. Davidson, MD, FACC*,*,
Thomas McGarry, MD, FACC ,
Robert Bettis, MD ,
Lorenzo Melani, MD, PhD ,
Leslie J. Lipka, MD, PhD, FACC,
Alexandre P. LeBeaut, MD,
Ramachandran Suresh, PhD,
Steven Sun, PhD,
Enrico P. Veltri, MD, FACC Ezetimibe Study Group
* Chicago Center for Clinical Research, Chicago, Illinois, USA
Oklahoma Foundation for Cardiovascular Research, Oklahoma City, Oklahoma, USA
Clinical Research Advantage, Edmonds Family Medicine Clinic, Edmonds, Washington, USA
Schering-Plough Research Institute, Kenilworth, New Jersey, USA
View larger version (29K):
[in a new window]
|
Figure 1 Study design. *Q1 = first qualifying LDL-C value using the Friedewald calculation; Q2 = second qualifying LDL-C value using the Friedewald calculation; blood samples for Q1 and Q2 were collected at least one week apart. Randomization to double-blind treatment occurred at Visit 4. NCEP = National Cholesterol Education Program.
|
|
View larger version (22K):
[in a new window]
|
Figure 2 Percentage change in direct low-density lipoprotein cholesterol (A), high-density lipoprotein cholesterol (B), and triglyceride (C) concentrations from baseline to end point. EZE = ezetimibe; Simva = simvastatin. Nonfilled columns = Simva; filled columns = Simva + EZE. In (A), the asterisk denotes p < 0.01, combination versus statin alone.
|
|
View larger version (29K):
[in a new window]
|
Figure 3 Mean percent change from baseline in plasma concentration of direct low-density lipoprotein cholesterol (LDL-C) over time and at end point. EZE = ezetimibe; Simva = simvastatin.
|
|
|
